{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:26:58Z","timestamp":1791617218807,"version":"4.3.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"University of Melbourne Early Career Researcher","award":["1655271"],"award-info":[{"award-number":["1655271"]}]},{"name":"Government National Health and Medical Research Council Career Development Fellowship","award":["APP1148372"],"award-info":[{"award-number":["APP1148372"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1093\/jac\/dky403","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T15:08:50Z","timestamp":1536419330000},"page":"218-227","source":"Crossref","is-referenced-by-count":40,"title":["Cost-effectiveness of 3\u2009months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study"],"prefix":"10.1093","volume":"74","author":[{"given":"Tan N","family":"Doan","sequence":"first","affiliation":[{"name":"Department of Medicine at the Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia"},{"name":"Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg J","family":"Fox","sequence":"additional","affiliation":[{"name":"Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T","family":"Meehan","sequence":"additional","affiliation":[{"name":"Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Scott","sequence":"additional","affiliation":[{"name":"The Burnet Institute, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Ragonnet","sequence":"additional","affiliation":[{"name":"Department of Medicine at the Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia"},{"name":"The Burnet Institute, Melbourne, Australia"},{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Viney","sequence":"additional","affiliation":[{"name":"Research School of Population Health, The Australian National University, Canberra, Australia"},{"name":"Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Trauer","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma S","family":"McBryde","sequence":"additional","affiliation":[{"name":"Department of Medicine at the Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia"},{"name":"Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,10,5]]},"reference":[{"key":"key\n\t\t\t\t2018121401542396700_dky403-B1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1378\/chest.12-0142","article-title":"Relevance of latent TB infection in areas of high TB prevalence","volume":"142","author":"Sharma","year":"2012","journal-title":"Chest"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chest.2015.11.017","article-title":"Risk of active tuberculosis in the five years following infection \u2026 15%?","volume":"149","author":"Trauer","year":"2016","journal-title":"Chest"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B3","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1183\/09031936.00214014","article-title":"Towards tuberculosis elimination: an action framework for low-incidence countries","volume":"45","author":"Lonnroth","year":"2015","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2471\/BLT.17.199414","article-title":"National policies on the management of latent tuberculosis infection: review of 98 countries","volume":"96","author":"Jagger","year":"2018","journal-title":"Bull World Health Organ"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B5","doi-asserted-by":"crossref","first-page":"20130437.","DOI":"10.1098\/rstb.2013.0437","article-title":"The ongoing challenge of latent tuberculosis","volume":"369","author":"Esmail","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B6","author":"World Health Organization","year":"2018"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B7","doi-asserted-by":"crossref","first-page":"146.","DOI":"10.1186\/s12879-017-2245-8","article-title":"Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine","volume":"17","author":"McClintock","year":"2017","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5588\/ijtld.12.0510","article-title":"Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population","volume":"17","author":"Jimenez-Fuentes","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B10","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","article-title":"Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study","volume":"166","author":"Page","year":"2006","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B11","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B13","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/imj.13601","article-title":"SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication","volume":"47","author":"Denholm","year":"2017","journal-title":"Intern Med J"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B14","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","article-title":"Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection","volume":"179","author":"Holland","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B15","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.5588\/ijtld.13.0423","article-title":"Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States","volume":"17","author":"Shepardson","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B16","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy230","article-title":"Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings","author":"Johnson","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B17","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B18","doi-asserted-by":"crossref","first-page":"104.","DOI":"10.1186\/s12916-017-0865-x","article-title":"Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis","volume":"15","author":"Mullie","year":"2017","journal-title":"BMC Med"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B19","doi-asserted-by":"crossref","first-page":"726.","DOI":"10.1186\/s12879-016-2064-3","article-title":"Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis","volume":"16","author":"Gomez","year":"2016","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B20","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/cid\/ciu066","article-title":"Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt","volume":"58","author":"Obach","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B21","author":"California Department of Public Health"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold","volume":"8","author":"Grosse","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/427802","article-title":"Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis","volume":"40","author":"Ena","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199709183371201","article-title":"A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration","volume":"337","author":"Whalen","year":"1997","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B25","first-page":"w13240","article-title":"Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis","volume":"141","author":"Fresard","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B26","first-page":"257","article-title":"Recent developments in treatment of latent tuberculosis infection","volume":"133","author":"Menzies","year":"2011","journal-title":"Indian J Med Res"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B27","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/DHPS.S68837","article-title":"Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study","volume":"6","author":"Denholm","year":"2014","journal-title":"Drug Healthc Patient Saf"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B29","first-page":"3617408.","article-title":"Acute and fatal isoniazid-induced hepatotoxicity: a case report and review of the literature","volume":"2016","author":"Kabbara","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jval.2012.09.006","article-title":"A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework","volume":"16","author":"Sadatsafavi","year":"2013","journal-title":"Value Health"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B31","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsa031667","article-title":"Priorities for the treatment of latent tuberculosis infection in the United States","volume":"350","author":"Horsburgh","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B32","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/j.ijid.2009.05.007","article-title":"Adherence to treatment of latent tuberculosis infection in a clinical population in New York City","volume":"14","author":"Li","year":"2010","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B33","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1378\/chest.122.5.1609","article-title":"Factors associated with the treatment of latent tuberculosis infection among health-care workers at a midwestern teaching hospital","volume":"122","author":"Shukla","year":"2002","journal-title":"Chest"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B34","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","journal-title":"Bull World Health Organ"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B35","author":"World Health Organization"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B36","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1001\/jamainternmed.2017.3941","article-title":"Cost-effectiveness of testing and treatment for latent tuberculosis infection in residents born outside the United States with and without medical comorbidities in a simulation model","volume":"177","author":"Tasillo","year":"2017","journal-title":"JAMA Intern Med"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B37","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.rmed.2014.01.010","article-title":"Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen","volume":"108","author":"Jo","year":"2014","journal-title":"Respir Med"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B38","doi-asserted-by":"crossref","first-page":"e17601.","DOI":"10.1371\/journal.pone.0017601","article-title":"Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review","volume":"6","author":"Tiemersma","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1164\/rccm.201501-0069OC","article-title":"Fluoroquinolone therapy for the prevention of multidrug-resistant tuberculosis in contacts. A cost-effectiveness analysis","volume":"192","author":"Fox","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t2018121401542396700_dky403-B40","doi-asserted-by":"crossref","first-page":"393.","DOI":"10.1186\/1471-2458-11-393","article-title":"Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review","volume":"11","author":"Long","year":"2011","journal-title":"BMC Public Health"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/1\/218\/27124671\/dky403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T20:03:14Z","timestamp":1571860994000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/1\/218\/5116208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,10,5]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky403","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2018,10,5]]}}}